PharmaPoint: Seasonal Influenza Vaccines – Global Drug Forecast and Market Analysis to 2025

Categories: Drugs by Therapeutic Area, Infectious Diseases Drugs, Pharmaceuticals

Price: $10,995

Description

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses designated as influenza types A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult.

Global seasonal influenza vaccine market generated about US$3.1 Billion in sales in 2015. It is expected that this market to experience solid growth, reaching sales of US$4.3 Billion by 2025 at a compound annual growth rate (CAGR) of 3.3%. The majority of this growth will occur in the 5EU, driven by the uptake of egg-based quadrivalent vaccines as the older and less expensive trivalent vaccines are gradually phased out. The seasonal influenza vaccines market in the 5EU is expected to grow at a CAGR of 5.5%, reaching sales of US$1.0 Billion by 2025.

It has identified the following factors as the main drivers for sales growth during the forecast period:
- After the amendments in the national immunization schedules of the US and the UK, these countries have introduced seasonal influenza vaccination of children in their respective routine immunization schedules, representing a major shift in the approach taken to prevent seasonal influenza infections. A shift in the national immunization programs towards routine vaccination of children across Germany, France, Spain, and Italy is also anticipated during the forecast period.
- The expansion of egg-based quadrivalent seasonal influenza vaccines across Germany, Italy, France, and Spain will improve clinical protection against influenza infections in European countries and drive market growth in Europe.
- The transition from egg-based to cell culture seasonal influenza vaccines is anticipated to further address public concerns of vaccine safety-such as egg-protein related allergies-and efficacy, maintaining global vaccination rates and driving market growth for seasonal influenza vaccines throughout the forecast period.

According to Christopher J. Pace, Ph.D.: “For the past few decades, children have not been the focus of season influenza immunization recommendations in developed nations. More recently, developed countries such as the US and the UK have issued expanded recommendations for the vaccination of healthy children and adolescents against seasonal influenza, thereby indirectly protecting high-risk groups such as the elderly and the immunocompromised from disease by disrupting community transmission. This generates a significant new opportunity for market penetration.”

The seasonal influenza vaccines marketplace has traditionally been dominated by Big Pharma, with Sanofi, GlaxoSmithKline (GSK), AstraZeneca/MedImmune, Novartis, and CSL Limited/Seqirus providing the majority of commercially available vaccines over the last decade. Smaller companies, such as Protein Sciences Corporation and Mylan, have entered the competitive landscape, but have so far been unable to acquire a significant market share across the 7MM. In 2015, the seasonal influenza vaccines market experienced additional changes, as Novartis fully retreated from the market by selling its vaccine portfolio to CSL Limited, leaving only four established companies to compete for the majority of market share in the 7MM.

The report “PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2025” provides an overview of seasonal influenza, including epidemiology, etiology, pathophysiology, as well current routine seasonal influenza vaccine recommendations of all 7MM covered.

In particular, this report covers the following:
- Provides detailed analysis about top-line seasonal influenza vaccine market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.
- Analysis of strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the seasonal influenza vaccine market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global seasonal influenza vaccine marketplace. Insightful review of the key industry drivers, restraints and challenges.

Companies mentioned in this report: GlaxoSmithKline, Sanofi Pasteur, CSL Limited (Seqirus), AstraZeneca (MedImmune), Protein Sciences Corporation, Mitsubishi Tanabe Pharma, Novavax.

Table of Contents

1. List of Tables and Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.1.3 Symptoms and Prognosis

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global Trends

4.3.1 Historical Perspective of Vaccination Coverage

4.3.2 Laboratory Confirmed Influenza Cases

4.3.3 Hospitalization Due to Influenza

4.3.4 Influenza Averted Cases

4.4 Forecast Methodology

4.4.1 Sources Used Tables

4.4.2 Forecast Assumptions and Methods

4.4.3 Sources Not Used

4.5 Epidemiological Forecast for Seasonal Influenza (2015-2025)

4.5.1 Seasonal Influenza Vaccination

4.5.2 Seasonal Influenza Vaccination Rates

4.5.3 Diagnosed Outpatient Influenza-Like Illness Incident Cases

4.5.4 Lab Confirmed Incident Cases of Seasonal Influenza

4.5.5 Influenza-Related Hospitalized Incident Cases

4.5.6 Cases Averted by Seasonal Influenza Vaccinations

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 Limitations of Analysis

4.6.3 Strengths of Analysis

5 Disease Management

5.1 Seasonal Influenza Immunization Policy

5.1.1 Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines

5.2 US

5.2.1 Influenza Immunization Recommendations and Policies

5.2.2 Clinical Practice

5.3 France

5.3.1 Influenza Immunization Recommendations and Policies

5.3.2 Clinical Practice

5.4 Germany

5.4.1 Influenza Immunization Recommendations and Policies

5.4.2 Clinical Practice

5.5 Italy

5.5.1 Influenza Immunization Recommendations and Policies

5.5.2 Clinical Practice

5.6 Spain

5.6.1 Influenza Immunization Recommendations and Policies

5.6.2 Clinical Practice

5.7 UK

5.7.1 Influenza Immunization Recommendations and Policies

5.7.2 Clinical Practice

5.8 Japan

5.8.1 Influenza Immunization Recommendations and Policies

5.8.2 Clinical Practice

6 Competitive Assessment

6.1 Overview

6.2 Product Profiles - Major Brands, Inactivated Vaccines

6.2.1 Fluzone Quadrivalent

6.2.2 Fluzone High-Dose

6.2.3 Fluzone Intradermal

6.2.4 Vaxigrip

6.2.5 Fluarix Tetra

6.2.6 Fluvirin

6.2.7 Afluria

6.2.8 Agrippal

6.3 Product Profiles - Major Brands, Inactivated Vaccines (Adjuvanted)

6.3.1 Fluad

6.4 Product Profiles - Major Brands, Live-Attenuated Vaccines

6.4.1 FluMist Quadrivalent

6.5 Product Profiles - Major Brands, Cell Cultured Vaccines

6.5.1 Flublok

6.5.2 Flucelvax

6.6 Other Seasonal Influenza Vaccines

6.6.1 Influvac

6.6.2 Minor Brands

7 Unmet Needs and Opportunity Analysis

7.1 Overview

7.2 Higher Level of Public Awareness and Positive Perception of Influenza Vaccines

7.2.1 Unmet Need

7.2.2 Gap Analysis

7.2.3 Opportunity

7.3 Immunization Policies Targeting Children and Adolescents

7.3.1 Unmet Need

7.3.2 Gap Analysis

7.3.3 Opportunity

7.4 Enhanced Vaccine Efficacy in High-Risk Groups

7.4.1 Unmet Need

7.4.2 Gap Analysis

7.4.3 Opportunity

7.5 Vaccines Leveraging Innovative and Efficient Manufacturing Technologies

7.5.1 Unmet Need

7.5.2 Gap Analysis

7.5.3 Opportunity

7.6 Improving the Cost-Effectiveness of Influenza Vaccines

7.6.1 Unmet Need

7.6.2 Gap Analysis

7.6.3 Opportunity

7.7 Vaccines with Broader Influenza Strain Coverage

7.7.1 Unmet Need

7.7.2 Gap Analysis

7.7.3 Opportunity

7.8 Improved Vaccine Safety Profile

7.8.1 Unmet Need

7.8.2 Gap Analysis

7.8.3 Opportunity

8 Pipeline Assessment

8.1 Overview

8.2 Promising Vaccines in Clinical Development

8.2.1 Seasonal Influenza VLP Vaccine

8.2.2 VN-100

8.2.3 Quadrivalent Seasonal Influenza VLP Vaccine

8.3 Promising Vaccines in Early-Stage Development

8.3.1 FLU-v

8.3.2 M-001

8.3.3 TAK-850

8.3.4 VAX-2012Q

8.4 Other Vaccines in Development Outside the 7MM

9 Current and Future Players

9.1 Overview

9.2 Trends in Corporate Strategy

9.3 Company Profiles - Major Players

9.3.1 Sanofi

9.3.2 CSL Limited (Seqirus)

9.3.3 GlaxoSmithKline

9.3.4 AstraZeneca (MedImmune)

9.3.5 Protein Sciences Corporation

9.3.6 Mitsubishi Tanabe Pharma

9.3.7 Novavax

9.4 Other Companies

9.4.1 Mylan

9.4.2 Daiichi Sankyo

10 Market Outlook

10.1 Global Markets

10.1.1 Forecast

10.1.2 Drivers and Barriers - Global Issues

10.2 US

10.2.1 Forecast

10.2.2 Key Events

10.2.3 Drivers and Barriers

10.3 France

10.3.1 Forecast

10.3.2 Key Events

10.3.3 Drivers and Barriers

10.4 Germany

10.4.1 Forecast

10.4.2 Key Events

10.4.3 Drivers and Barriers

10.5 Italy

10.5.1 Forecast

10.5.2 Key Events

10.5.3 Drivers and Barriers

10.6 Spain

10.6.1 Forecast

10.6.2 Key Events

10.6.3 Drivers and Barriers

10.7 United Kingdom

10.7.1 Forecast

10.7.2 Key Events

10.7.3 Drivers and Barriers

10.8 Japan

10.8.1 Forecast

10.8.2 Key Events

10.8.3 Drivers and Barriers

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.4 Forecasting Methodology

11.4.1 Vaccine Coverage

11.4.2 Vaccines Included

11.4.3 Key Launch Dates

11.4.4 Influenza Vaccine Tender System Assumptions

11.4.5 General Pricing Assumptions

11.4.6 Individual Vaccine Assumptions

11.4.7 Pricing of Pipeline Agents

11.5 Primary Research - KOLs Interviewed for this Report

11.6 Primary Research - Prescriber Survey

11.7 About the Authors

11.7.1 Analyst

11.7.2 Therapy Area Director

11.7.3 Epidemiologists

11.7.4 Director of Epidemiology

11.7.5 Global Director of Therapy Analysis and Epidemiology

11.8 About

11.9 Disclaimer

List of Tables

Table 1: Notable Influenza Pandemics

Table 2: Influenza Symptoms

Table 3: Risk Factors and Comorbidities for Seasonal Influenza

Table 4: 7MM, Historical Perspective of Seasonal Influenza Vaccination Coverage

Table 5: 7MM, Sources of Epidemiological Data Used to Forecast Total Population Vaccination Rates of Seasonal Influenza

Table 6: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Incident Cases of Outpatient Seasonal ILI

Table 7: 7MM, Sources of Epidemiological Data Used to Forecast Laboratory Confirmed Incident Cases of Seasonal Influenza

Table 8: 7MM, Sources of Epidemiological Data Used to Forecast Seasonal Influenza-Related Hospitalized Incident Cases

Table 9: 7MM, Sources of Epidemiological Data Used to Forecast Averted Cases of Seasonal Influenza

Table 10: 7MM, Sources Not Used in Epidemiological Analysis of Seasonal Influenza

Table 11: 7MM, People Receiving Seasonal Influenza Vaccination, All Ages, Both Sexes, N, Selected Years 2015-2025

Table 12: 7MM, Age-Specific Distribution of People Receiving Seasonal Influenza Vaccination, Both Sexes, N (Row %), 2015

Table 13: 7MM, Sex-Specific Distribution of People Receiving Seasonal Influenza Vaccination, All Ages, N (Row %), 2015

Table 14: 7MM, Seasonal Influenza Vaccination Rates, All Ages, Both Sexes, %, Selected Years 2015-2025

Table 15: 7MM, Age-Specific Seasonal Influenza Vaccination Rates, Both Sexes, (%), 2015

Table 16: 7MM, Diagnosed Outpatient ILI Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025

Table 17: 7MM, Age-Specific Diagnosed Outpatient ILI Incident Cases, Both Sexes, N (Row %), 2015

Table 18: 7MM, Sex-Specific Diagnosed Outpatient ILI Incident Cases, All Ages, N (Row %), 2015

Table 19: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, Both Sexes, N, Selected Years 2015-2025

Table 20: 7MM, Age-Specific Lab Confirmed Incident Cases of Seasonal Influenza, Both Sexes, N (Row %), 2015

Table 21: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, N (Row %), 2015

Table 22: 7MM, Influenza-Related Hospitalized Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025

Table 23: 7MM, Age-Specific Influenza-Related Hospitalized Incident Cases, Both Sexes, N (Row %), 2015

Table 24: 7MM, Influenza Related Hospitalized Incident Cases, All Ages, N (Row %), 2015

Table 25: 7MM, Cases Averted by Seasonal Influenza Vaccinations, All Ages, Both Sexes, N, Selected Years 2015-2025

Table 26: 7MM, Age-Specific Cases Averted by Seasonal Influenza Vaccinations, Both Sexes, N (Row %), 2015

Table 27: Seasonal Influenza Immunization Recommendation Agencies by Country, 2016

Table 28: Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines, 2016

Table 29: Country Profile - US

Table 30: Country Profile - France

Table 31: Country Profile - Germany

Table 32: Country Profile - Italy

Table 33: Country Profile - Spain

Table 34: Country Profile - UK

Table 35: Country Profile -Japan

Table 36: Leading Seasonal Influenza Vaccines, 2016

Table 37: Product Profile - Fluzone Quadrivalent

Table 38: Immunogenicity Profile of Fluzone Quadrivalent

Table 39: Local and Systemic AEs of Fluzone Quadrivalent

Table 40: Fluzone Quadrivalent SWOT Analysis, 2016

Table 41: Global Sales Forecast ($m) for Fluzone Quadrivalent, 2015-2025

Table 42: Product Profile - Fluzone High-Dose

Table 43: Immunogenicity of Fluzone High-Dose Compared with Fluzone

Table 44: Local and Systemic AEs of Fluzone High-Dose

Table 45: Fluzone High-Dose SWOT Analysis, 2016

Table 46: Global Sales Forecast ($m) for Fluzone High-Dose, 2015-2025

Table 47: Product Profile - Fluzone Intradermal

Table 48: Comparison of Fluzone Intradermal Quadrivalent Versus Fluzone Intradermal Trivalent

Table 49: Local andsystemic AEs of Fluzone Intradermal Quadrivalent

Table 50: Fluzone Intradermal Quadrivalent SWOT Analysis, 2016

Table 51: Global Sales Forecast ($m) for Fluzone/Intanza Intradermal, 2015-2025

Table 52: Product Profile - Vaxigrip

Table 53: Cumulative Incidence of Influenza Infection in Children

Table 54: Local and Systemic AEs of Vaxigrip

Table 55: Vaxigrip SWOT Analysis, 2016

Table 56: Global Sales Forecast ($m) for Vaxigrip, 2015-2025

Table 57: Product Profile - Fluarix Tetra

Table 58: Immunogenicity Profile of Fluarix Tetra

Table 59: Local and Systemic AEs of Fluarix Tetra

Table 60: Fluarix Tetra SWOT Analysis, 2016

Table 61: Global Sales Forecast ($m) for Fluarix Tetra, 2015-2025

Table 62: Product Profile - Fluvirin

Table 63: Immunogenicity of Fluvirin in Adults

Table 64: Local and Systemic AEs of Fluvirin

Table 65: Fluvirin SWOT Analysis, 2016

Table 66: Global Sales Forecast ($m) for Fluvirin, 2015-2025

Table 67: Product Profile - Afluria

Table 68: Immunogenicity of Afluria in Adults

Table 69: Local and Systemic AEs of Afluria

Table 70: Afluria SWOT Analysis, 2016

Table 71: Global Sales Forecast ($m) for Afluria, 2015-2025

Table 72: Product Profile - Agrippal

Table 73: Immunogenicity of Agrippal

Table 74: Local and Systemic AEs of Agrippal

Table 75: Agrippal SWOT Analysis, 2016

Table 76: Global Sales Forecast ($m) for Agrippal, 2015-2025

Table 77: Product Profile - Fluad

Table 78: Immunogenicity Comparison of Fluad Versus Agriflu

Table 79: Local and Systemic AEs of Fluad

Table 80: Fluad SWOT Analysis, 2016

Table 81: Global Sales Forecast ($m) for Fluad, 2015-2025

Table 82: Product Profile - FluMist Quadrivalent

Table 83: Noninferiority of FluMist Quadrivalent Compared with FluMist Trivalent

Table 84: AEs of FluMist Quadrivalent

Table 85: FluMist Quadrivalent SWOT Analysis, 2016

Table 86: Global Sales Forecast ($m) for FluMist Quadrivalent, 2015-2025

Table 87: Product Profile - Flublok

Table 88: Immunogenicity of Flublok compared with Fluzone and Fluzone High-Dose

Table 89: Local and Systemic AEs of Flublok

Table 90: Flublok SWOT Analysis, 2016

Table 91: Global Sales Forecast ($m) for Flublok, 2015-2025

Table 92: Product Profile - Flucelvax

Table 93: Immunogenicity of Flucelvax

Table 94: Local and Systemic AEs of Flucelvax

Table 95:Flucelvax SWOT Analysis, 2016

Table 96: Global Sales Forecast ($m) for Flucelvax, 2015-2025

Table 97: Summary of Other Marketed Seasonal Influenza Vaccines, 2016

Table 98: Unmet Need and Opportunity in Seasonal Influenza Vaccines, 2016

Table 99: Seasonal Influenza Vaccines - Late-Stage Pipeline, 2016

Table 100: Quadrivalent Versions of Marketed Vaccines

Table 101: Product Profile - Seasonal Influenza VLP Vaccine

Table 102: Seasonal Influenza VLP Vaccine SWOT Analysis, 2016

Table 103: Global Sales Forecast ($m) for Seasonal Influenza VLP Vaccine, 2015-2025

Table 104: Product Profile - VN-100

Table 105: Comparison of Immunogenicity Profile of VN-100 and Subcutaneous Standard Vaccine

Table 106: Frequency of Local and Systemic AEs of VN-100 Compared with a Comparator Subcutaneous Vaccine

Table 107: VN-100 SWOT Analysis, 2016

Table 108: Global Sales Forecast ($m) for VN-100, 2015-2025

Table 109: Product Profile - Quadrivalent Seasonal Influenza VLP Vaccine

Table 110: Quadrivalent Seasonal Influenza VLP Vaccine SWOT Analysis, 2016

Table 111: Global Sales Forecast ($m) for Quadrivalent Seasonal Influenza VLP Vaccine, 2015-2025

Table 112: Promising Vaccines in Early-Stage Development, 2016

Table 113: Summary of Seasonal Influenza Vaccines in Development Outside the 7MM, 2016

Table 114: Key Companies in the Seasonal Influenza Vaccines Market, 2016

Table 115: Sanofi’s Seasonal Influenza Vaccine Portfolio Assessment, 2016

Table 116: CSL Limited’s Seasonal Influenza Vaccine Portfolio Assessment, 2016

Table 117: GSK’s Seasonal Influenza Vaccine Portfolio Assessment, 2016

Table 118: AstraZeneca’s Seasonal Influenza Vaccine Portfolio Assessment, 2016

Table 119: Protein Sciences Corporation’s Seasonal Influenza Vaccine Portfolio Assessment, 2016

Table 120: Mitsubishi’s Seasonal Influenza Vaccine Portfolio Assessment, 2016

Table 121: Novavax’s Seasonal Influenza Vaccine Portfolio Assessment, 2016

Table 122: Global (7MM) Sales Forecasts ($m) for Seasonal Influenza Vaccines, 2015-2025

Table 123: Seasonal Influenza Vaccines Market - Drivers and Barriers, 7MM, 2015-2025

Table 124: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the US, 2015-2025

Table 125: Key Events Impacting Sales for Seasonal Influenza in the US, 2015?2025

Table 126: US Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015?2025

Table 127: Sales Forecasts ($m) for Seasonal Influenza Vaccines in France, 2015 -2025

Table 128: Key Events Impacting Sales for Seasonal Influenza in France, 2015?2025

Table 129: France Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015?2025

Table 130: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Germany, 2015 -2025

Table 131: Key Events Impacting Sales for Seasonal Influenza in Germany, 2015?2025

Table 132: Germany Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015?2025

Table 133: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Italy, 2015-2025

Table 134: Key Events Impacting Sales for Seasonal Influenza in Italy, 2015?2025

Table 135: Italy Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015?2025

Table 136: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Spain, 2015 -2025

Table 137: Key Events Impacting Sales for Seasonal Influenza in Spain, 2015?2025

Table 138: Spain Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015?2025

Table 139: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the UK, 2015-2025

Table 140: Key Events Impacting Sales for Seasonal Influenza in the UK, 2015?2025

Table 141: UK Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015?2025

Table 142: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Japan, 2015-2025

Table 143: Key Events Impacting Sales for Seasonal Influenza in Japan 2015?2025

Table 144: Japan Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015?2025

Table 145: Key Launch Dates

Table 146: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Influenza Virus Structure

Figure 2: 7MM, Cases with Seasonal Influenza Vaccination, All Ages, Both Sexes, N, 2015-2025

Figure 3: 7MM, Age-Specific Cases with Seasonal Influenza Vaccination, Both Sexes, N, 2015

Figure 4: 7MM, Sex-Specific Distribution of People Receiving Seasonal Influenza Vaccination, All Ages, N, 2015

Figure 5: 7MM, Seasonal Influenza Vaccination Rates, All Ages, Both Sexes, %, 2015-2025

Figure 6: 7MM, Age-Specific Seasonal Influenza Vaccination Rates, Both Sexes, (%), 2015

Figure 7: 7MM, Diagnosed Outpatient ILI Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025

Figure 8: 7MM, Age-Specific Diagnosed Outpatient ILI Incident Cases, Both Sexes, N, 2015

Figure 9: 7MM, Sex-Specific Diagnosed Outpatient ILI Incident Cases, All Ages, N, 2015

Figure 10: 7MM, Age-Standardized Diagnosed Outpatient ILI Incidence, All Ages, Cases per 100,000 Population, 2015

Figure 11: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, Both Sexes, N, Selected Years 2015-2025

Figure 12: 7MM, Age-Specific Lab Confirmed Incident Cases of Seasonal Influenza, Both Sexes, N, 2015

Figure 13: 7MM, Lab Confirmed Incident Cases of Seasonal Influenza, All Ages, N, 2015

Figure 14: 7MM, Influenza-Related Hospitalized Incident Cases, All Ages, Both Sexes, N, Selected Years 2015-2025

Figure 15: 7MM, Age-Specific Influenza-Related Hospitalized Incident Cases, Both Sexes, N, 2015

Figure 16: 7MM, Influenza-Related Hospitalized Incident Cases, All Ages, N, 2015

Figure 17: 7MM, Cases Averted by Seasonal Influenza Vaccinations, All Ages, Both Sexes, N, Selected Years 2015-2025

Figure 18: 7MM, Age-Specific Cases Averted by Seasonal Influenza Vaccinations, Both Sexes, N, 2015

Figure 19: Seasonal Influenza Vaccines - Phase II/Phase III Pipeline, 2016

Figure 20: Competitive Assessment of the Late-Stage Pipeline Vaccines for Seasonal Influenza, 2015-2025

Figure 21: Company Portfolio Gap Analysis in Seasonal Influenza Vaccines, 2015-2025

Figure 22: Global (7MM) Sales for Seasonal Influenza Vaccines by Country, 2015 and 2025

Figure 23: Sales of Seasonal Influenza Vaccines by Class in the US, 2015 and 2025

Figure 24: Sales of Seasonal Influenza Vaccines by Class in France, 2015 and 2025

Figure 25: Sales of Seasonal Influenza Vaccines by Class in Germany, 2015 and 2025

Figure 26: Sales of Seasonal Influenza Vaccines by Class in Italy, 2015 and 2025

Figure 27: Sales of Seasonal Influenza Vaccines by Class in Spain, 2015 and 2025

Figure 28: Sales of Seasonal Influenza Vaccines by Class in the UK, 2015 and 2025

Figure 29: Sales of Seasonal Influenza Vaccines by Class in Japan, 2015 and 2025

Companies Mentioned

  • Sanofi
  • CSL Limited (Seqirus)
  • GlaxoSmithKline
  • AstraZeneca (MedImmune)
  • Protein Sciences Corporation
  • Mitsubishi Tanabe Pharma
  • Novavax
  • Mylan
  • Daiichi Sankyo